Mackenzie Financial’s Mersana Therapeutics MRSN Stock Holding History

Mackenzie Financial’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-33,834	Closed	-$967K	–	1630
2025 Q4	$967K	Sell	33,834 -13,985	-29%	-$266K	﹤0.01%	1067
2025 Q3	$371K	Buy	+47,819	New	+$359K	﹤0.01%	1338
2025 Q1	–	Sell	-3,678	Closed	-$131K	–	1753
2024 Q4	$131K	Buy	+3,678	New	+$190K	﹤0.01%	1611
2024 Q2	–	Sell	-553	Closed	-$61.9K	–	1593
2024 Q1	$61.9K	Buy	+553	New	+$55K	﹤0.01%	1469
2023 Q2	–	Sell	-2,753	Closed	-$283K	–	1589
2023 Q1	$283K	Sell	2,753 -195	-7%	-$27.4K	﹤0.01%	1206
2022 Q4	$432K	Buy	+2,948	New	+$498K	﹤0.01%	975
2020 Q2	–	Sell	-4,231	Closed	-$617K	–	1089
2020 Q1	$617K	Buy	+4,231	New	+$739K	﹤0.01%	771

Other funds holding MRSN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mackenzie Financial's MRSN Position: Q1 2026 in Review

Mackenzie Financial sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 33,834 shares — an estimated $967K sold.

Mackenzie Financial first reported a position in MRSN in Q1 2020 and held it in 7 quarters. The position peaked at $967K in Q4 2025. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.

Mackenzie Financial reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
Mackenzie Financial sold 33,834 Mersana Therapeutics shares in Q1 2026, an estimated $967K.
Mackenzie Financial first reported a position in Mersana Therapeutics in Q1 2020 and held it in 7 quarters.
Mackenzie Financial's Mersana Therapeutics position peaked at $967K in Q4 2025.
1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.